INTRODUCTION AND OBJECTIVES: Gemcitabine (GEM) and cisplatin (CDDP) combination chemotherapy (GC) is the standard treatment for patients with advanced bladder cancer (BC), but responses have been reported in only 60% of patients, and these are rarely durable. We aimed to use a genomic analysis to determine mechanisms of resistance to GC.
METHODS: Three chemo-sensitive BC cell lines were treated serially with increasing concentrations of CDDP or GEM in order to establish acquired resistance. Gene expression of the resistant cells was compared to the sensitive parental cells. Results were validated in The Cancer Genome Atlas (n[405) and in a patient cohort treated with neoadjuvant GC (n[223). Immunohistochemistry (IHC) was performed in 14 patient tumors before and after neoadjuvant GC and in 37 patients with metastatic BC treated with GC. Correlative in vitro experiments were conducted to explore the mechanism of acquired chemo-resistance.
RESULTS: Gene expression analysis revealed that STAT1 and six interferon-regulated genes were among the most highly upregulated genes in resistant cells. In the TCGA dataset, STAT1 expression correlated with the expression of the other 6 genes (P<0.001). Highest STAT1 expression was observed in basal/ squamous and luminal infiltrated subtypes. Five-year survival in these patients treated without neoadjuvant GC was 49.7% and 47.7% in tumors with high and low STAT1 expression (compared the median), respectively. In a cohort of patients treated with neoadjuvant GC, the corresponding survival was 62.7% and 78.9%. Nuclear STAT1 expression by IHC was absent in tumors prior to GC but detected in 29% after GC, suggesting that GC activates STAT1 in a subset of patients. In patients with metastatic BC, STAT1 expression was higher in patients with progressive disease (P[0.078) and high STAT1 expression correlated with worse prognosis (P[0.012). Knockdown of STAT1 in resistant cells without CDDP/GEM treatment increased cell growth by cell cycle progression, which was accompanied by increased SKP2 and decreased p27. However, STAT1 knockdown with CDDP/GEM treatment decreased cell growth and increased apoptosis, suggesting that STAT1 silencing restored sensitivity to GC.
CONCLUSIONS: STAT1 signaling is activated in a subset of BC patients and is associated with acquired chemotherapy resistance. Pending further validation, STAT1 may be considered as potential target in combination with GC, as well as a predictive marker of response to GC.
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INTRODUCTION AND OBJECTIVES:
Previous studies demonstrated ERCC2 helicase domain mutations confer nucleotide excision repair (NER) deficiency and drive cisplatin sensitivity in muscle invasive bladder cancer (MIBC). We sought to investigate the role of spironolactone (SP), a NER inhibitor in potentiating cisplatin response in NER proficient bladder cancer cells and patient derived organoids.
METHODS: KE1 (ERCC2 mutant, NER defective, cisplatin sensitive) bladder cells and parental KU1919 cells (ERCC2 wild-type, NER proficient, cisplatin resistant) were used. Cell viability was examined using CellTiter-glo. IC50 concentrations were calculated using a four parameter sigmoidal model and plots generated by GraphPad Prism 7. Drug combination indexes (CI) of cisplatin and SP were calculated using Chou-Talalay method. DNA damage response and apoptosis signaling was examined by Western blot of gamma-H2AX, P53, cleaved Caspase-3 and cleaved PARP.
RESULTS: KU1919 cells are more sensitive to SP (IC50 [ 29.2 vs IC50 [ 37.4 mM). Combinations of cisplatin and SP (5 mM:40 mM) resulted in strong synergy in KU1919 cells (CI [ 0.29), whereas mild synergy of cisplatin and SP (1 mM:40 mM) was observed in KE1 cells (CI [ 0.66) . In a patient derived organoid model, 10 µM SP alone exhibited no cytotoxicity, and combination with 10 mMSP and 25 mMcisplatin significantly decreased cell survival compared with 25 mM cisplatin alone (17.9% vs 32.1%, p<0.01). Following 24 hours 5 mM cisplatin
